NCT02595502

Brief Summary

The purpose of this investigation is to evaluate the short-term, clinical performance of two silicone hydrogel daily disposable contact lenses.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
286

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Sep 2015

Shorter than P25 for not_applicable

Geographic Reach
1 country

13 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2015

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2015

Completed
1 day until next milestone

First Submitted

Initial submission to the registry

November 2, 2015

Completed
1 day until next milestone

First Posted

Study publicly available on registry

November 3, 2015

Completed
9 months until next milestone

Results Posted

Study results publicly available

July 20, 2016

Completed
Last Updated

July 5, 2017

Status Verified

June 1, 2017

Enrollment Period

2 months

First QC Date

November 2, 2015

Results QC Date

June 10, 2016

Last Update Submit

June 13, 2017

Conditions

Outcome Measures

Primary Outcomes (1)

  • Overall Comfort

    Overall comfort was assessed using the Contact Lens User Experienceâ„¢ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient-experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120. Please note this was a 2 treatment by 3 period study design. Therefore, some subjects were randomized to receive one of the study lenses twice, hence the number of observations were summarized per lens type. For the senofilcon A lens 134+138+134=406 (Observations- 1 per subject per period, however 1 observation was not recorded) from period 1, 2 and 3 respectively. For the delefilcon A lens 138+134+138=410 from period 1, 2 and 3 respectively.

    1 Week

Study Arms (2)

Sequence 1: Test Control Test

ACTIVE COMPARATOR

Test/control/test using the Johnson \& Johnson Vision Care (JJVC) Marketed contact lens (test) and the Competitor Marketed contact lens (control). Lenses will be worn as daily wear, daily disposable on both eyes for approximately one week each in between lenses for total study duration of approximately three weeks per subject. Subjects are required to wear the lenses at least five days for at least eight hours per day worn.

Device: JJVC Marketed Contact Lens (Test)Device: Competitor Marketed Contact Lens (Control)

Sequence 2: Control Test Control

ACTIVE COMPARATOR

Control/test/control using the JJVC Marketed contact lens (test) and the Competitor Marketed contact lens (control). Lenses will be worn as daily wear, daily disposable on both eyes for approximately one week each for total study duration of approximately three weeks per subject. Subjects are required to wear the lenses at least five days for at least eight hours per day worn.

Device: JJVC Marketed Contact Lens (Test)Device: Competitor Marketed Contact Lens (Control)

Interventions

Also known as: senofilcon A
Sequence 1: Test Control TestSequence 2: Control Test Control
Also known as: delefilcon A
Sequence 1: Test Control TestSequence 2: Control Test Control

Eligibility Criteria

Age18 Years - 39 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
  • The subject must appear able and willing to adhere to the instructions set forth in this clinical protocol.
  • The subject must be between (and including) 18 and 39 years of age.
  • The subject must be an adapted wearer of spherical soft contact lenses in both eyes. That is, the subject must wear their habitual lenses at least five (5) days per week and eight (8) hours per day worn for at least 30 days immediately preceding the study.
  • The subject must have vertex-corrected distance refraction that allows a plano over-refraction with the available contact lens powers of -0.50 to -6.00 Diopters (D) in each eye.
  • The subject must have refractive astigmatism, if present, of less than or equal to 1.00 D in each eye.
  • The subject must have best corrected visual acuity of 20/25 or better in each eye.

You may not qualify if:

  • Currently pregnant or breastfeeding (subjects who become pregnant during the study will be discontinued).
  • Any ocular or systemic allergies or diseases that may interfere with contact lens wear.
  • Any autoimmune disease or use of medication, which may interfere with contact lens wear.
  • Entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, or aphakia.
  • Any previous, or planned, ocular or interocular surgery (e.g., radial keratotomy, photorefractive keratectomy (PRK), laser-assisted in situ keratomileusis (LASIK), etc.).
  • Any grade 3 or greater slit lamp findings (e.g., edema, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival injection) on the FDA classification scale, any previous history or signs of a contact lens-related corneal inflammatory event (e.g., past peripheral ulcer or round peripheral scar), or any other ocular abnormality that may contraindicate contact lens wear.
  • Any ocular infection.
  • Any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear.
  • Monovision, multi-focal, toric, or extended wear contact lens correction.
  • Participation in any contact lens or lens care product clinical trial within 14 days prior to study enrollment.
  • History of binocular vision abnormality or strabismus that is likely to affect successful contact lens wear.
  • Any infectious disease (e.g., hepatitis, tuberculosis) or contagious immunosuppressive diseases (e.g., HIV) by self-report.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (13)

Becky Bizzle, OD

Montgomery, Alabama, 36117, United States

Location

Complete Family Eye Care of Fruit Cove

Fruit Cove, Florida, 32259, United States

Location

Golden Family Eyecare

Sarasota, Florida, 34232, United States

Location

St. Lucy's Vision Center

Tampa, Florida, 33625, United States

Location

Eye Associates of Winter Park

Winter Park, Florida, 32792, United States

Location

VisualEyes, Inc.

Roswell, Georgia, 30076, United States

Location

Advantage Eyecare Associates, LLC

Neodesha, Kansas, 66757, United States

Location

Sacco Eye Group

Vestal, New York, 13850, United States

Location

Advanced Family Eye Care

Denver, North Carolina, 28037, United States

Location

total Eye Care PA

Memphis, Tennessee, 38119, United States

Location

Brian Frazier, OD

Jacksonville, Texas, 17576, United States

Location

Timothy R. Poling, OD

Roanoke, Virginia, 24153, United States

Location

Ziegler Leffingwell Eyecare

West Allis, Wisconsin, 53227, United States

Location

MeSH Terms

Conditions

Vision Disorders

Condition Hierarchy (Ancestors)

Sensation DisordersNeurologic ManifestationsNervous System DiseasesEye DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Results Point of Contact

Title
Brian Pall, O.D., M.S., F.A.A.O - Senrior Principal Research Optometrist
Organization
Johnson & Johnson Vision Care Inc.

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
GT60
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 2, 2015

First Posted

November 3, 2015

Study Start

September 1, 2015

Primary Completion

November 1, 2015

Study Completion

November 1, 2015

Last Updated

July 5, 2017

Results First Posted

July 20, 2016

Record last verified: 2017-06

Locations